Optum Ventures co-led a round for Icometrix, the developer of a diagnostics system for neurological disorders, with Forestay Capital and Capricorn Venture Partners.
Phathom Pharmaceuticals has been launched with $140m in debt and equity financing to commercialise a gastrointestinal disease drug licensed from Takeda.
Gregor Kevrekian, previously senior director of CVS Health’s corporate development and venture investing business, has ascended to executive director.
René Pompl, formerly principal at Siemens’ Next47, has joined the corporate’s medical-focused Healthineers division as manager of venture technology.
Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.
JSR and SymBiosis took part in an $18.5m series C extension for PureTech spinoff Vedanta, growing the Bristol-Myers Squibb and PureTech Health-backed round to $45.5m.
JD.com has secured CICC Capital, Baring Private Equity Asia and CPEChina Fund for a series A round expected to value its healthcare spinoff at $6.9bn.
The Posco-backed pulmonary device maker has collected $65m in an oversubscribed round led by Ally Bridge Group, taking its equity funding to $135m to date.
The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.
Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
